Recent Updates
Recently added Catalysts

MK-8644

Phase 1

Psoriasis | Small Molecules | Dermatology |Merck & Company, Inc.|Trials Updated: Oct 27, 2026

MK-8644 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Sep 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment132

FDA Designations

No designations recorded

MK-8644 clinical trials

MK-8644 · 1 trial · 2 indications

Phase 1 1
NCT07850310A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)Psoriasis
RECRUITING132 Analytics
PHASE1RECRUITING
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
PsoriasisUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants Who Experience an Adverse Event (AE)
Up to approximately 43 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

Number of Participants Who Discontinue Study Due to an AE
Up to approximately 28 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

Secondary Endpoints

Plasma Concentration at 24 Hours (C24) of MK-8644
At designated timepoints up to 24 hours post-dose
Maximum Plasma Concentration (Cmax) of MK-8644
Predose and at designated timepoints up to 4 days post-dose
Time to Maximum Plasma Concentration (Tmax) of MK-8644
Predose and at designated timepoints up to 4 days post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
MK-8644EXPERIMENTALParticipants receive MK-8644 orally under fasted or fed conditions depending on randomization.
PlaceboPLACEBO_COMPARATORParticipants receive matching placebo for MK-8644 orally under fasted or fed conditions depending on randomization.

Interventions

NameTypeDescription
MK-8644DRUGOral administration
Placebo for MK-8644DRUGOral administration
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a BMI between 18 and 36 kg/m\^2, inclusive Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of clinically signific...

Countries:Australia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 27, 2026NCT07850310Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 27, 2026NCT07850310Status: NOT_YET_RECRUITING → RECRUITING
LOWSep 30, 2026NCT07850310NEW_TRIAL: changed
LOWSep 30, 2026NCT07850310NEW_TRIAL: changed

Frequently asked questions about MK-8644

What is MK-8644 used for in psoriasis?

MK-8644 is an investigational small molecule being developed by Merck for psoriasis. It is in Phase 1 clinical development, and the only listed trial enrolls both healthy participants and participants with psoriasis to evaluate the drug in a placebo-controlled, double-blind, randomized setting.

Who makes MK-8644?

MK-8644 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is running the Phase 1 program for the compound, including the trial listed as MK-8644-001 in Australia.

What phase is MK-8644 in?

MK-8644 is in Phase 1 clinical development. It is an investigational small molecule for psoriasis and has not completed any trials in the listed program. One Phase 1 trial is currently recruiting, with a planned enrollment of 132 participants.

What clinical trials is MK-8644 in?

MK-8644 is being studied in trial NCT07850310, titled A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001). It is a recruiting Phase 1 trial in Australia with 132 planned participants, randomized, double-blind, and placebo-controlled, enrolling adults 18 years and older.

Is MK-8644 a small molecule?

Yes, MK-8644 is a small molecule. It is an investigational oral-style small molecule drug in Phase 1 development at Merck for psoriasis, studied in a randomized, double-blind, placebo-controlled trial that includes both healthy volunteers and participants with psoriasis.